Merck, Lundbeck end development of Phase III insomnia drug

Share this article:
Merck and Lundbeck have scrapped their joint-development program for insomnia treatment gaboxadol. In a joint-statement, the companies said data from recently completed clinical studies suggests the overall clinical profile for gaboxadol “does not support further development.” As a result Merck and Lundbeck said they will not file a new drug application (NDA) with the FDA or other regulatory agencies. Ongoing clinical studies are to be terminated. In October, Lundbeck and Merck extended the target date to submit a NDA for gaboxadol with the FDA to mid-2007 from the first quarter of 2007, because of slower than anticipated enrollment in ongoing Phase III trials. The companies agreed in 2004 to collaborate on the development and commercialization of gaboxadol in the US Lundbeck would have received a milestone payment of $75 million from Merck if it moved forward with an application for US registration of gaboxadol.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.